February 13, 2020 / 1:27 PM / 10 days ago

BRIEF-Scynexis Completes Patient Enrollment In Study Of Vaginal Yeast Infection Treatment

Feb 13 (Reuters) - SCYNEXIS Inc:

* SCYNEXIS COMPLETES PATIENT ENROLLMENT AHEAD OF SCHEDULE IN THE SECOND PIVOTAL PHASE 3 STUDY (VANISH-306) OF ORAL IBREXAFUNGERP FOR THE TREATMENT OF VULVOVAGINAL CANDIDIASIS (VAGINAL YEAST INFECTION)

* SCYNEXIS INC - TOP-LINE DATA EXPECTED IN EARLY Q2 OF 2020

* SCYNEXIS INC - NDA SUBMISSION OF ORAL IBREXAFUNGERP FOR TREATMENT OF VAGINAL YEAST INFECTIONS IS ON TRACK FOR SECOND HALF OF 2020

* SCYNEXIS INC - SUPPLEMENTAL NDA SUBMISSION OF PHASE 3 CANDLE STUDY OF ORAL IBREXAFUNGERP ANTICIPATED IN SECOND HALF OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below